Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.

Revenue
+19.2%
EPS
+64.1%
Free cash flow
−29.8%
Total debt
−5.19%

Quarter to September 2026, against a year earlier

146.38 9.74 −6.24%
Market cap
$10.8B
P/E
25.2×
Fwd P/E
24.4×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
8 9 6 6

+8 more TTM periods

ROE
28.94% 26.02% 23.00% 18.12%
ROA
13.31% 11.31% 9.31% 7.87%
ROIC
18.77% 17.56% 17.90% 16.94%
Return on Tangible Assets
19.98% 19.11% 16.35% 12.03%
Average Days of Receivables
78.86 70.37 68.54 69.67
Free Cash Flow per Share
3.75 3.83 5.54 4.97
Free Cash Flow
260.00 265.60 387.80 349.90
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026